Journal
CLINICAL JOURNAL OF PAIN
Volume 25, Issue 4, Pages 286-292Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/AJP.0b013e318192bf87
Keywords
pain assessment; neuropathic pain; Neuropathic Pain Scale; pain quality; postherpetic neuralgia
Categories
Funding
- Depomed Inc
- Endo Pharmaceuticals and Depomed Inc
Ask authors/readers for more resources
Objective: To replicate and extend previous research concerning the validity and utility of using pain quality measures in clinical trials. Methods: One hundred fifty-eight patients with moderate-to-severe postherpetic neuralgia were randomly assigned to I of 3 treatment conditions: (1) extended release gabapentin (G-ER) 1800 mg once-daily administered in the evening; (2) G-ER 1800 mg asymmetric divided dose (600 mg ANI and 1200 mg PM); or (3) placebo G-ER. A measure of different pain qualities. the Neuropathic Pain Scale, was administered as a secondary measure in this study before, during, and after the treatment. Results: The results suggest that G-ER, especially when administered twice-daily, have the greatest effects on sharp, dull, sensitive, and itchy pain. Few between-condition effects were found for the global ratings of intensity or unpleasantness, and for hot, cold, deep, or surface pain qualities. Conclusions: The results provide further Support for the importance of assessing specific pain qualities as outcomes in clinical trials. The findings may also be used by clinicians for identifying those patients for whom G-ER may be particularly effective, that is, patients with postherpetic neuralgia presenting with pain described as sharp, dull, sensitive, or itchy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available